In The News
Stay informed with the latest research breakthroughs, treatment updates, and community stories related to Parkinson’s disease.
Use of newly named drug leads to stable motor symptoms in Parkinson’s
Small study shows benefits at 1 year with oral therapy once called GT-02287 Written by Andrea Lobo | Oct. 6, 2026 The oral Parkinson's therapy candidate rexaceract, formerly GT-02287, was shown to stabilize motor symptoms in patients in an early trial. Treatment with...
Blue light therapy glasses show promise for Parkinson’s sleep
Study participants report sleep quality, daytime alertness improvements Written by Andrea Lobo | Oct. 6, 2026 Patients with Parkinson’s disease frequently experience debilitating sleep disturbances and excessive daytime sleepiness. Wearing blue light therapy glasses...
Pivotal trial of adaptive deep brain stimulation device hits key milestone
Newronika's AlphaDBS system implanted in first Parkinson's study patient Written by Patricia Inácio, PhD | Oct. 7, 2026 The first Parkinson’s disease patient has been implanted with Newronika‘s adaptive AlphaDBS, an innovative deep brain stimulation (DBS) system, as...
Brain chemical changes may be tied to Parkinson’s cognitive issues
Study highlights role of cerebellum in Parkinson's learning, memory problems Written by Marisa Horak, MS | Oct. 8, 2026 Chemical changes in the cerebellum, particularly involving the neurotransmitter glutamate, are linked to cognitive impairment in Parkinson's...
Combined cognitive, biomarker testing targets Parkinson’s, related disorders
Amprion, Prema Cognition collaboration aims to identify, evaluate those at risk Written by Andrea Lobo | Oct. 9, 2026 Amprion and Prema Cognition are partnering to identify and evaluate people at risk of developing Parkinson's and related disorders. The approach pairs...
First patient dosed in Phase 2a oral therapy trial for Parkinson’s disease
RESET will assess safety, drug exposure, and biological markers over 12 weeks Written by Andrea Lobo | Oct. 12, 2026 Parkinson’s disease is characterized by the loss of dopamine-producing nerve cells, which contributes to movement difficulties and cognitive changes....
Psychiatric issues often manageable during Parkinson’s infusion therapy
Study found new events in 22% of patients, often eased by dose changes Written by Marisa Horak, MS | Oct. 13, 2026 Patients starting the advanced Parkinson’s disease treatment Vyalev may experience new psychiatric issues, particularly hallucinations or psychosis....
First patient dosed in clinical trial of oral treatment for Parkinson’s
Study testing Mission Therapeutics' therapy recruiting in several locations Written by Andrea Lobo | Oct. 19, 2026 The first patient was dosed in a Phase 1b clinical trial testing MTX325, an oral treatment for Parkinson’s. The trial is still recruiting participants at...
Think tank outlines 8 key steps to eliminate Parkinson’s
Research funding, chemical bans among suggestions from experts Written by Marisa Horak, MS | Oct. 16, 2026 Experts outlined an eight-step strategy focused on primary prevention to eliminate Parkinson’s disease and address rising incidence rates. Key risk factors...
Short nutrition course may improve life for Parkinson’s patients
4-week program on food-med interaction boosts physical, mental quality of life Written by Michela Luciano, PhD | Oct. 15, 2026 Dietary proteins compete with Parkinson's medication for intestinal absorption and brain transport. A four-week nutrition education program...